Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel
NYSEAMERICAN:ARMP

Armata Pharmaceuticals Q1 2026 Earnings Report

Armata Pharmaceuticals logo
$5.37 -0.06 (-1.10%)
As of 08/28/2026 04:10 PM Eastern
ProfileEarnings HistoryForecast

Armata Pharmaceuticals EPS Results

Actual EPS
-$3.16
Consensus EPS
-$0.38
Beat/Miss
Missed by -$2.78
One Year Ago EPS
N/A

Armata Pharmaceuticals Revenue Results

Actual Revenue
$0.79 million
Expected Revenue
$0.74 million
Beat/Miss
Beat by +$49.00 thousand
YoY Revenue Growth
N/A

Armata Pharmaceuticals Announcement Details

Quarter
Q1 2026
Date
5/13/2026
Time
Before Market Opens
Conference Call Date
Wednesday, May 13, 2026
Conference Call Time
8:00AM ET

Upcoming Earnings

Armata Pharmaceuticals' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Armata Pharmaceuticals' Q1 2026 Press ReleasePress Release
(8-K)
Armata Pharmaceuticals' Q1 2026 Quarterly reportQuarterly report
(10-Q)

Armata Pharmaceuticals Earnings Headlines

Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
August 13, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69299644-armata-pharmaceuticals-inc-armata-pharmaceuticals-announces-financial-results-for-the-second-quarter-2026-and-provides-a-corporate-update-008.htm
Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
July 20, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69070494-armata-pharmaceuticals-inc-armata-pharmaceuticals-achieves-key-progress-across-clinical-regulatory-and-manufacturing-activities-supporting-planned-008.htm
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
August 29 at 1:00 AM  |  Altimetry (Ad)
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
July 20, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/armata-pharmaceuticals-achieves-key-progress-across-clinical-regulatory-and-manufacturing-activities-supporting-planned-phase-3-initiation-of-ap-sa02-302829265.html
Armata Pharmaceuticals: Promising Phage Platform, But Phase 3 Is Everything
July 17, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4923054-armata-pharmaceuticals-promising-phage-platform-but-phase-3-is-everything
Armata Pharmaceuticals Stock Short Interest Report | AMEX:ARMP | Benzinga
July 13, 2026  |  benzinga.comhttps://www.benzinga.com/quote/ARMP/short-interest
See More Armata Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Armata Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Armata Pharmaceuticals and other key companies, straight to your email.

About Armata Pharmaceuticals

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens. Its lead program, AP-PA02, has advanced into early-stage clinical evaluation, while additional efforts focus on preclinical development of therapies for diabetic foot infections and anthrax prophylaxis. The company collaborates with U.S. government agencies on biodefense and public health initiatives, underscoring the potential utility of its phage platform in addressing both emerging and established bacterial threats.

Founded in 2017 and headquartered in Horsham, Pennsylvania, Armata Pharmaceuticals serves the U.S. market with an eye toward global expansion as clinical data emerge. The company is led by Chairman and Chief Executive Officer George Eliopoulos, whose experience in infectious disease drug development guides Armata’s strategic partnerships and research efforts. Through its innovative biologics approach, Armata aims to deliver safer and more effective treatments for patients facing life-threatening bacterial infections.

View Armata Pharmaceuticals Profile
Earnings Tools